title: Systematic review and meta-analysis of the role of somatostatin and its analogues in the treatment of enterocutaneous fistula.
abstract: OBJECTIVE
  Somatostatin analogues may help pancreatic fistula although it remains unclear whether they help nonpancreatic fistula. This study involved meta-analysis of somatostatin analogues for treatment of enterocutaneous fistula.
  
  
  METHODS
  Meta-analysis of studies was undertaken, to estimate the effect of somatostatin analogues on spontaneous closure, time to closure and mortality.
  
  
  RESULTS
  Results showed significant associations between somatostatin and both spontaneous closure rate [odds ratio (OR) 6.61, 95% (CI) confidence interval 1.35-32.43] and time to closure (standardized mean difference -0.80, 95% CI: -1.34 to -0.26). Octreotide reduced closure time (standardized mean difference -0.57, 95% CI: -0.95 to -0.20) but not spontaneous closure (OR: 1.74, 95% CI: 0.64-4.76). Lanreotide also improved time to closure (mean of 17 days vs. 26 days, standard deviation not stated) but not spontaneous closure (OR: 0.94, 95% CI: 0.42-2.12). Somatostatin, octreotide and lanreotide did not significantly affect mortality (OR: 0.30, 0.82, and 0.48; 95% CI: 0.03-3.47, 0.38-1.78, and 0.04-5.07 respectively).
  
  
  CONCLUSIONS
  Somatostatin and octreotide improved fistula closure time but only somatostatin improved spontaneous closure rate.
authors.affiliation: Department of General Surgery, Nevill Hall Hospital, Abergavenny, Wales, UK. Stevens_P1@hotmail.com
authors.forename: Philip
authors.initials: P
authors.lastname: Stevens
authors.forename: Rhiannon E
authors.initials: RE
authors.lastname: Foulkes
authors.forename: Jake S
authors.initials: JS
authors.lastname: Hartford-Beynon
authors.forename: Raymond J
authors.initials: RJ
authors.lastname: Delicata
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007412:Intestinal Fistula / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D005765:Gastrointestinal Agents; D013004:Somatostatin; D015282:Octreotide